Press releases
Read more:
Categories
2021
2021-06-02 08:44
Nanologica Recruits VP Drug Development
To accelerate the development of the NLAB Spiro® inhalation platform, Ulf Ericsson has been recruited as VP Drug Development. The position includes...
2021-05-17 07:58
Nanologica’s Patent Application Published
The invention relates to new pharmaceutical compositions, their use as medical treatments and particularly to their administration to the lung to treat...
2021-05-05 14:11
Nanologica Publishes Annual Report for 2020
Nanologica hereby announces that the annual report for 2020 has been published. The report is available on the company’s website www.nanologica.com...
2021-04-23 08:18
Nanologica Interim Report Jan-Mar 2021
IMPORTANT MILESTONES ACHIEVED IN BOTH BUSINESS AREAS Successful upscaling of the production of silica to ton scale advances Nanologica’s position...
2021-04-21 09:54
Nanologica Announces Date Change for Annual Report
Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual Report 2020...
2021-04-13 08:38
Nanologica’s Nomination Committee Proposes Thomas Eldered as New Board Member of Nanologica AB
Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute of Technology and is the co-founder of Recipharm AB...
2021-04-13 08:00
Nanologica’s Nomination Committee Proposes Thomas Eldered as New Board Member of Nanologica AB
Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the...
In addition, the date for the interim report for the second quarter 2021 has been changed from August 27, 2021 to July 9, 2021. Financial calendar 2021...
Nanologica’s drug delivery platforms NLAB Spiro® and NLAB Silica™ consists of nanoporous particles where APIs can be placed inside the...